Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research, development, licensing, and acquisition of innovative therapeutics to treat a range of human illnesses. Shares of the biopharma company are soaring 75% through early trading on Wednesday, June 1, 2022. Over the past three months, Tonix Pharmaceuticals has seen average daily volume of around 2.04 million shares. However, volume of 84.98 million shares or dollar volume of around $373.91 million, has already exchanged hands through early trading.
Shares of Tonix Pharmaceuticals are surging after the company announced that it has been issued U.S. Patent No. 11,345,896 from the U.S. Patent and Trademark Office. The patent is entitled “Synthetic Chimeric Poxviruses,” which covers the company’s monkeypox, smallpox, horsepox vaccines and recombinant Pox Virus (RPV) platform technology. Tonix Pharmaceuticals will have market exclusivity through 2037, unless the patent is extended.
Tonix’s vaccine candidates, TNX-801, TNX-1840, and TNX-1850 are all protected under the issuance. The TNX-801 candidate is a live virus vaccine that is based on synthesized horsepox. The TNX-801 candidate is also being used as a framework to develop similar vaccines for monkeypox and smallpox. Molecular data from DNA sequences have suggested that the TNX-801 candidate are “closer than modern smallpox vaccines to the vaccine discovered and disseminated by Dr. Edward Jenner in 1798,” according to the company.
TNX-1840 and TNX-1850 are horsepox-based live virus vaccines that are being developed to treat COVID-19, specifically omicron and BA.2 variants. The TNX-1840 and 1850 candidates are designed to express the spike protein in the COVID variants.
“This patent is an important milestone in protecting our expanding pipeline of vaccines that address known and potentially novel pathogens,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. “TNX-801 is a horsepox-based live virus vaccine currently in development to protect against monkeypox and smallpox. TNX-18401 and TNX-18501 are designed to express the spike proteins from the SARS-CoV-2 omicron and BA.2 variants, respectively. Horsepox was one of the first few viruses ever generated by synthetic biology and remains among the largest. As we prepare to advance horsepox-based live virus vaccines into clinical development, we are excited to have this new patent as an important element of our patent estate.”
Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/